Schistosoma mansoni tetraspanning orphan receptor (SmTOR): A new vaccine candidate against schistosomiasis

Clinical and Experimental Immunology

Volumn 170, Issue 3, 2012, Pages 342-357

  Lochmatter, C ^a   Schneider, C L ^a   Ingram, K ^b   Keiser, J ^b   Schifferli, J A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Complement regulation; Schistosoma mansoni tetraspanning orphan receptor (SmTOR); Schistosomiasis; Tegument protein; Vaccine candidate

Indexed keywords

COMPLEMENT COMPONENT C2; FREUND ADJUVANT; RECEPTOR ANTIBODY; RECOMBINANT FIRST EXTRACELLULAR DOMAIN OF SCHISTOSOMA MANSONI TETRASPANNING ORPHAN RECEPTOR; SCHISTOSOMA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCHISTOSOMIASIS; SERUM; VACCINATION;

ANIMALS; ANTIBODIES, HELMINTH; ANTIBODY SPECIFICITY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINES;

EID: 84868257738     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04667.x     Document Type: Article

References (59)

1. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003; 3:733-744.
2. Bilharz T, Von Siebold CT. A contribution to human helminthology. Zeitsch Wissensch Zool 1852-53; 4:53-76.
3. Jordan P. From katayama to the Dakhla Oasis: the beginning of epidemiology and control of bilharzia. Acta Trop 2000; 77:9-40.
4. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411-425.
5. Abdul-Ghani R, Loutfy N, el-Sahn A, Hassan A. Current chemotherapy arsenal for Schistosomiasis mansoni: alternatives and challenges. Parasitol Res 2009; 104:955-965.
6. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21:659-667.
7. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007; 11:433-439.
8. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61:294-303.
9. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21:225-242.
10. McManus DP. The search for a vaccine against schistosomiasis - a difficult path but an achievable goal. Immunol Rev 1999; 171:149-161.
11. Hagan P. Schistosomiasis - a rich vein of research. Parasitology 2009; 136:1611-1619.
12. Berriman M, Haas BJ, LoVerde PT etal. The genome of the blood fluke Schistosoma mansoni. Nature 2009; 460:352-358.
13. Hokke CH, Fitzpatrick JM, Hoffmann KF. Integrating transcriptome, proteome and glycome analyses of Schistosoma biology. Trends Parasitol 2007; 23:165-174.
14. Wilson RA, Ashton PD, Braschi S, Dillon GP, Berriman M, Ivens A. 'Oming in on schistosomes: prospects and limitations for post-genomics. Trends Parasitol 2007; 23:14-20.
15. Loukas A, Tran M, Pearson MS. Schistosome membrane proteins as vaccines. Int J Parasitol 2007; 37:257-263.
16. Wilson RA, Coulson PS. Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz 2006; 101 (Suppl. 1):13-20.
17. Braschi S, Borges WC, Wilson RA. Proteomic analysis of the shistosome tegument and its surface membranes. Mem Inst Oswaldo Cruz 2006; 101:205-212.
18. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics 2006; 6:1471-1482.
19. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006; 5:347-356.
20. Hansell E, Braschi S, Medzihradszky KF etal. Proteomic analysis of skin invasion by blood fluke larvae. PLoS Negl Trop Dis 2008; 2:e262.
21. Skelly PJ. Immunoparasitology series: intravascular schistosomes and complement. Trends Parasitol 2004; 20:370-374.
22. Lochmatter C, Schifferli JA, Martin PJ. Schistosoma mansoni TOR is a tetraspanning orphan receptor on the parasite surface. Parasitology 2009; 136:487-498.
23. Inal JM, Schifferli JA. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2. J Immunol 2002; 168:5213-5221.
24. Zeng G. Sticky-end PCR: new method for subcloning. Biotechniques 1998; 25:206-208.
25. Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Exp Purif 2005; 41:207-234.
26. Soulard A, Cremonesi A, Moes S, Schutz F, Jeno P, Hall MN. The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates. Mol Biol Cell 2010; 21:3475-3486.
27. Hurst R, Hook B, Slater MR, Hartnett J, Storts DR, Nath N. Protein-protein interaction studies on protein arrays: effect of detection strategies on signal-to-background ratios. Anal Biochem 2009; 392:45-53.
28. Los GV, Encell LP, McDougall MG etal. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 2008; 3:373-382.
29. Cardoso FC, Macedo GC, Gava E etal. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2008; 2:e308.
30. Manneck T, Haggenmüller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 2010; 137:85-98.
31. Dubendorff JW, Studier FW. Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor. J Mol Biol 1991; 219:45-59.
32. Inal JM, Sim RB. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett 2000; 470:131-134.
33. Inal JM. Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite. Biochim Biophys Acta 1999; 1445:283-298.
34. Ramos CR, Spisni A, Oyama S Jr etal. Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate. Biochim Biophys Acta 2009; 1794:655-662.
35. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004; 22:460-466.
36. El Ridi R, Wagih A, Salem R, Mahana N, El Demellawy M, Tallima H. Impact of interleukin-1 and interleukin-6 in murine primary schistosomiasis. Int Immunopharmacol 2006; 6:1100-1108.
37. El Ridi R, Salem R, Wagih A, Mahana N, El Demellawy M, Tallima H. Influence of interleukin-2 and interferon-gamma in murine schistosomiasis. Cytokine 2006; 33:281-288.
38. El Ridi R, Mahrous A, Afifi A, Montash M, Velek J, Jezek J. Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to Schistosomiasis. Scand J Immunol 2001; 54:477-485.
39. Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631-1640.
40. Bergquist NR, Colley DG. Schistosomiasis vaccine:research to development. Parasitol Today 1998; 14:99-104.
41. Pinot de Moira A, Fulford AJ, Kabatereine NB, Ouma JH, Booth M, Dunne DW. Analysis of complex patterns of human exposure and immunity to Schistosomiasis mansoni: the influence of age, sex, ethnicity and IgE. PLoS Negl Trop Dis 2010; 4:e820.
42. Capron A, Dessaint JP. Immunologic aspects of schistosomiasis. Annu Rev Med 1992; 43:209-218.
43. Moser G, Sher A. Studies of the antibody-dependent killing of schistosomula of Schistosoma mansoni employing haptenic target antigens. II. In vitro killing of TNP-schistosomula by human eosinophils and neutrophils. J Immunol 1981; 126:1025-1029.
44. Horowitz S, Tarrab-Hazdai R, Eshhar Z, Arnon R. Anti-schistosome monoclonal antibodies of different isotypes - correlation with cytotoxicity. EMBO J 1983; 2:193-198.
45. Gounni AS, Lamkhioued B, Ochiai K etal. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367:183-186.
46. Moqbel R, MacDonald AJ, Kay AB. Enhancement of human eosinophil- and neutrophil-mediated killing of schistosomula of Schistosoma mansoni by reversed type (IgE-mediated) anaphylaxis in vitro. Clin Exp Immunol 1985; 59:577-586.
47. Kazura JW, Fanning MM, Blumer JL, Mahmoud AA. Role of cell-generated hydrogen peroxide in granulocyte-mediated killing of schistosomula of Schistosoma mansoni in vitro. J Clin Invest 1981; 67:93-102.
48. Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. Immunization of mice with Co-60 irradiated Schistosoma mansoni cercariae. Am J Trop Med Hyg 1978; 27:76-86.
49. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21:112-117.
50. Tendler M, Simpson AJ. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008; 108:263-266.
51. Da'Dara AA, Skelly PJ, Walker CM, Harn DA. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite Immunol 2003; 25:429-437.
52. Da'dara AA, Skelly PJ, Wang MM, Harn DA. Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice. Vaccine 2001; 20:359-369.
53. Tran MH, Pearson MS, Jeffrey MB etal. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835-840.
54. Farias LP, Cardoso FC, Miyasato PA etal. Schistosoma mansoni stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLoS Negl Trop Dis 2010; 4:e597.
55. Kariuki TM, Farah IO, Yole DS etal. Parameters of the attenuated schistosome vaccine evaluated in the olive baboon. Infect Immun 2004; 72:5526-5529.
56. Wilson RA, Coulson PS. Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite's armour. Trends Parasitol 2009; 25:423-431.
57. Horak P, Kolarova L. Bird schistosomes: do they die in mammalian skin? Trends Parasitol 2001; 17:66-69.
58. Lichtenbergova L, Kolbekova P, Kourilova P etal. Antibody responses induced by Trichobilharzia regenti antigens in murine and human hosts exhibiting cercarial dermatitis. Parasite Immunol 2008; 30:585-595.
59. Chamot E, Toscani L, Rougemont A. Public health importance and risk factors for cercarial dermatitis associated with swimming in Lake Leman at Geneva, Switzerland. Epidemiol Infect 1998; 120:305-314.